Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01526070 · ClinicalTrials.gov registry record
Study of Bimonthly VEGF Trap-Eye Compared to As-needed Administration or Other Therapy for Exudative Age-Related Macular Degeneration
A clinical trial of Exudative Age-Related Macular Degeneration, sponsored by Stanford University.
- Completed
- Registry status
- 142
- Enrollment target
- 1
- Study location
NCT01526070: Completed study of Exudative Age-Related Macular Degeneration, sponsored by Stanford University.
NCT01526070 is a study of Exudative Age-Related Macular Degeneration that has completed, run by Stanford University. The registered enrollment target is 142 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01526070, a study of Exudative Age-Related Macular Degeneration, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- 142 participants
- Enrollment target
- 1
- Study location
Study Summary
Over the last several years, the standard of care for wet macular degeneration has become treatment with intravitreal injections of ranibizumab (Lucentis, Genentech), administered as frequently as every 4 weeks. In contrast, clinical trials of a soluble VEGF receptor, Aflibercept/VEGF Trap-Eye (Eylea, Regeneron Pharmaceuticals) have demonstrated maintained anatomic and visual improvement with many fewer injections (typically monthly injections for 3 months, followed by every-other-month injections, and as few as 5 injections a year). The purpose of this study is to determine whether patients who have switched from ranibizumab to VEGF Trap-Eye have comparable results.
Conditions Studied
Interventions
- DRUG Intravitreal injection of Aflibercept
Study Locations (1)
California
- Byers Eye Institute at Stanford - Palo Alto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2012-01 |
| Est. Completion | 2014-07 |
What the finished NCT01526070 record still lists
NCT01526070 is an observational study that tracks outcomes without assigning an intervention. The registered 142 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Exudative Age-Related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention - of which Intravitreal injection of Aflibercept is the first listed.
NCT01526070 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01526070 about?
NCT01526070 is a clinical study titled "Study of Bimonthly VEGF Trap-Eye Compared to As-needed Administration or Other Therapy for Exudative Age-Related Macular Degeneration". Over the last several years, the standard of care for wet macular degeneration has become treatment with intravitreal injections of ranibizumab (Lucentis, Genentech), administered as frequently as every 4 weeks. In contrast, clinical trials of a soluble VEGF receptor, Aflibercept/VEGF Trap-Eye (Eyle...
What is the current status of trial NCT01526070?
This trial is currently completed. The enrollment target is 142 participants. The study started on 2012-01. Estimated completion is 2014-07.
What conditions does trial NCT01526070 study?
This clinical trial studies the following conditions: Exudative Age-Related Macular Degeneration.
What interventions are being tested in trial NCT01526070?
The interventions under investigation include: Intravitreal injection of Aflibercept (DRUG).
Who is sponsoring clinical trial NCT01526070?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01526070 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Exudative Age-Related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03933631 · 142 participants · Phase 3
Pilocarpine Use After Kahook Goniotomy
- NCT04938349 · 142 participants · NA
Dual Task Perturbation Training for OAwMCI
- NCT06117254 · 142 participants · NA
Hearing Aids for Veterans With Functional Hearing Difficulties
- NCT06463665 · 142 participants · Phase 2
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia